Pharma-Bio Serv, Inc 8-K, filed Jun 15, 2020
Pharma-Bio Serv, Inc. (PBSV)
8-K
2020-06-15
For: 2020-06-15
View Original
Added on
April 06, 2026
About this 8-K
Pharma-Bio Serv, Inc filed this 8-K on June 15, 2020.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): June 15,
2020
Pharma-Bio Serv, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
0-50956
|
20-0653570
|
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
6 Road
696, Dorado, Puerto Rico
|
00646
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(787)
278-2709
|
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b2 of
the Securities Exchange Act of 1934 (17 CFR §240.12b2).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition
On June
15, 2020, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing
its results of operations for the quarter ended April 30, 2020. A
copy of the press release is furnished as Exhibit 99.1 to this report
The
information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities under that section and shall not be deemed to be
incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
Press
Release, dated June 15, 2020
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
PHARMA-BIO
SERV, INC.
|
|
|
|
|
|
|
|
|
Date:
June 15, 2020
|
By:
|
/s/ Pedro
J. Lasanta
|
|
|
|
|
Pedro
J. Lasanta
|
|
|
|
|
Chief
Financial Officer, Vice President Finance and Administration and
Secretary
|
|
|
|
|
|
|
3
Exhibit 99.1
Pharma-Bio Serv Announces Results for the Quarter Ended April 30,
2020
June 15, 2020
DORADO, PUERTO RICO / ACCESSWIRE / June 15, 2020 /
Pharma-Bio Serv, Inc. ("Pharma-Bio
Serv" or the "Company") (OTCQB:PBSV), a compliance, project
management and technology transfer support consulting firm that
provides services to the pharmaceutical, biotechnology, chemical,
medical device, cosmetic, food and allied products industries,
today announced revenues for the three and six months ended April
30, 2020 were $5,648,000 and $10,261,000, respectively, an increase
of approximately $498,000 and $545,000, or 9.7% and 5.6%,
respectively, when compared to the same periods last
year.
Net income for the three and six months ended April 30, 2020 was
approximately $688,000 and $1,214,000, respectively, reflecting no
significant change when compared to the same periods last
year.
“As the coronavirus (COVID-19) pandemic continues, our
resources, services and expertise remain dedicated to the
operations and quality objectives that are critical to our
customers. We continue to actively monitor the pandemic and any
potential impacts it may have on our business and results of
operations for the third quarter and potentially beyond”,
said Victor Sanchez, CEO of Pharma-Bio Serv, Inc.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv is a compliance, project management, and technology
transfer support consulting firm, headquartered in Puerto Rico,
servicing the Puerto Rico, United States, Europe and Brazil
markets. Pharma-Bio Serv's core business is FDA and international
agencies regulatory compliance consulting related services. The
Company's global team includes leading engineering and life science
professionals, quality assurance managers and
directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the
meaning of the U.S. federal securities laws, which statements may
include information regarding the plans, intentions, expectations,
future financial performance, or future operating performance of
Pharma-Bio Serv. Forward-looking statements are based on the
expectations, estimates, or projections of management as of the
date of this news release. Although Pharma-Bio Serv's management
believes these expectations, estimates, or projections to be
reasonable as of the date of this news release, forward-looking
statements are inherently subject to significant business risks,
economic uncertainties, including any impacts of the coronavirus
(COVID-19) pandemic, and competitive uncertainties, or other
contingencies, which could cause its actual results or performance
to differ materially from what may be expressed or implied in the
forward-looking statements. Important factors that could cause
Pharma-Bio Serv's actual results or performance to differ
materially from the forward-looking statements include those set
forth in the "Risk Factors" section of Pharma-Bio Serv's Annual
Report on Form 10-K for the year ended October 31, 2019, and in its
other filings with the Securities and Exchange Commission, which
filings are available on www.sec.gov.
Pharma-Bio Serv disclaims any intention or obligation to update or
revise any forward-looking statements to reflect subsequent events
and circumstances, except to the extent required by applicable
law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv,
Inc.